162 related articles for article (PubMed ID: 10121154)
21. Expanded and early access and patient assistance programs for other experimental drugs from their manufacturers.
Crit Path AIDS Proj; 1998; (No 33):43-64. PubMed ID: 11366373
[TBL] [Abstract][Full Text] [Related]
22. Big money, little science?
Nat Immunol; 2008 Nov; 9(11):1199. PubMed ID: 18936775
[No Abstract] [Full Text] [Related]
23. Patient group seeks overhaul of FDA clinical trial system in court.
Hede K
J Natl Cancer Inst; 2006 Sep; 98(18):1268-70. PubMed ID: 16985242
[No Abstract] [Full Text] [Related]
24. Lobbyists anticipate more money for all.
Macilwain C; Smaglik P
Nature; 2000 Jan; 403(6766):123. PubMed ID: 10671144
[No Abstract] [Full Text] [Related]
25. Patients as citizen advocates.
Morra ME
Cancer Pract; 1997; 5(1):55-7. PubMed ID: 9128498
[No Abstract] [Full Text] [Related]
26. Anguish and opportunity.
Kosterlitz J
Natl J (Wash); 1990 Apr; 22(17):1008-15. PubMed ID: 10170540
[TBL] [Abstract][Full Text] [Related]
27. NIH's way of setting priorities endorsed.
Wadman M
Nature; 1998 Mar; 392(6672):116. PubMed ID: 9515947
[No Abstract] [Full Text] [Related]
28. Can single-patient investigational new drug studies hurry slow trains to the fast track?
Chenoweth D
Drug Discov Today; 2006 Mar; 11(5-6):185-6. PubMed ID: 16580594
[TBL] [Abstract][Full Text] [Related]
29. Today's threat is tomorrow's crisis: advocating for dental education, dental and biomedical research, and oral health.
Bresch JE; Luke GG; McKinnon MD; Moss MJ; Pritchard D; Valachovic RW
J Dent Educ; 2006 Jun; 70(6):601-6. PubMed ID: 16741127
[TBL] [Abstract][Full Text] [Related]
30. New office and new leader aim to streamline FDA cancer drug review process.
Twombly R
J Natl Cancer Inst; 2005 May; 97(10):708-9. PubMed ID: 15900036
[No Abstract] [Full Text] [Related]
31. AIDS research come to patients' home towns.
Young FE
FDA Consum; 1989 May; 23(4):6-7. PubMed ID: 10313019
[No Abstract] [Full Text] [Related]
32. Bush accused of power abuse over science.
Check E
Nature; 2003 Aug; 424(6950):715. PubMed ID: 12917651
[No Abstract] [Full Text] [Related]
33. Duke's hazards. Did medical experiments put patients needlessly at risk?
Kaplan S; Brownlee S
US News World Rep; 1999 May; 126(20):66-8, 70. PubMed ID: 10387890
[No Abstract] [Full Text] [Related]
34. Avoiding legal and ethical pitfalls of industry-sponsored research: the co-existence of research, scholarship, and marketing in the pharmaceutical industry.
Dorfman HL; Reig LP
Food Drug Law J; 2004; 59(4):595-615. PubMed ID: 15880876
[No Abstract] [Full Text] [Related]
35. A delicate balancing act.
Nat Rev Drug Discov; 2007 Sep; 6(9):685. PubMed ID: 17907339
[No Abstract] [Full Text] [Related]
36. National Research Service Awards. Final rule.
National Institutes of Health. Department of Health and Human Services
Fed Regist; 2001 May; 66(105):29498-501. PubMed ID: 11725763
[TBL] [Abstract][Full Text] [Related]
37. U.S. House of Representatives moves to dismantle NIH AIDS research program. National Institutes of Health.
Update Natl Minor AIDS Counc; 1995; ():6. PubMed ID: 11362790
[TBL] [Abstract][Full Text] [Related]
38. Research Lobbying: researchers fight for a voice.
Anderson C
Nature; 1990 Nov; 348(6299):270. PubMed ID: 2250693
[No Abstract] [Full Text] [Related]
39. Comments from the former Chief Medical Officer of the American Cancer Society (1968-1988).
Holleb AI
Cancer; 1996 Dec; 78(12):2590-1. PubMed ID: 8952569
[No Abstract] [Full Text] [Related]
40. Bush favors boosting AIDS research, but other funding static.
AIDS Policy Law; 2002 Feb; 17(3):1, 4. PubMed ID: 11873552
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
